Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates

By sjmartinez • March 5, 2025

Pala L, Merlo F, Sala I, Pagan E, Oriecuia C, Specchia C, Catania C, Cocorocchio E, Laszlo D, Ceresoli G, Locatelli M, De Pas T, Zambelli A, Cortes J, Giaccone G, Moore KN, Bardia A, Viale G, Gelber RD, Bagnardi V, Conforti F. Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates. J Natl Cancer Inst. 2025 Feb 25:djaf049. doi: 10.1093/jnci/djaf049. Epub ahead of print. PMID: 40036179.

Tags: Hematology/Oncology, Publications

Goserelin 3-month depot shows non-inferiority to the monthly formulation in U.S. patients with premenopausal breast cancer: a real-world evidence study

McCann KE, Osman N, Cannon J, Brent L, Wang Y, Tepsick J, Mandora PV, Miller V, Martin N, Kaklamani VG. Goserelin 3-month depot shows non-inferiority[...]

A plain language summary of quality of life with sacituzumab govitecan treatment in the TROPiCS-02 study in participants with breast cancer (HR-positive/HER2-negative)

Rugo HS, Schmid P, Tolaney SM, Marmé F, Bardia A, Spears PA, Cortés J. A plain language summary of quality of life with sacituzumab govitecan[...]

Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study

Nassar AH, Abou Alaiwi S, El Zarif T, Denu R, Macaron W, Abdel-Wahab N, Freeman D, Vasbinder A, Hayeck S, Anderson E, Goodman RS, Johnson[...]